

Naomi S Coombes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9721717/publications.pdf>

Version: 2024-02-01

14
papers

10,149
citations

566801

15
h-index

887659

17
g-index

21
all docs

21
docs citations

21
times ranked

19085
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021, 397, 99-111.	6.3	3,887
2	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. <i>Lancet, The</i> , 2020, 396, 467-478.	6.3	2,080
3	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet, The</i> , 2020, 396, 1979-1993.	6.3	1,196
4	Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. <i>Cell</i> , 2021, 184, 2348-2361.e6.	13.5	936
5	Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. <i>Cell</i> , 2021, 184, 2201-2211.e7.	13.5	442
6	Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. <i>Nature Structural and Molecular Biology</i> , 2020, 27, 846-854.	3.6	434
7	Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. <i>Cell Host and Microbe</i> , 2020, 28, 445-454.e6.	5.1	298
8	Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays. <i>Nature Protocols</i> , 2021, 16, 3114-3140.	5.5	195
9	Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity. <i>Nature Communications</i> , 2021, 12, 81.	5.8	141
10	A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction. <i>Nature Communications</i> , 2020, 11, 4198.	5.8	132
11	Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19. <i>Nature Communications</i> , 2021, 12, 1260.	5.8	115
12	Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations. <i>British Journal of Pharmacology</i> , 2021, 178, 626-635.	2.7	73
13	Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 by Disrupting the Spike-ACE2 Interaction. <i>ACS Central Science</i> , 2022, 8, 527-545.	5.3	62
14	mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant. <i>ELife</i> , 2021, 10, .	2.8	28